| CAS ID: | 1365970-03-1 |
| Molecular Formula: | C38H46F4N6O9S |
| Molecular Weight: | 838.9 g/mol |
| Monoisotopic Mass: | 838.2983 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | ABT-493 | GLECAPREVIR | A-1282576.0 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1 | See All |
| InChI Key: | MLSQGNCUYAMAHD-ITNVBOSISA-N | |
| Smiles: | CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC\C=C\C(F)(F)c3nc4ccccc4nc3O[C@@H]5C[C@H](N(C5)C1=O)C(=O)N[C@@]6(C[C@H]6C(F)F)C(=O)NS(=O)(=O)C7(C)CC7 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT03089944 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Active, not recruiting |
| First Received | March 24, 2017 | Last Verified | March 22, 2019 |
| Sponsor | AbbVie | ||
Trial Record 2
| ClinicalTrial ID | NCT01995071 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 26, 2013 | Last Verified | October 16, 2017 |
| Sponsor | AbbVie | ||
Trial Record 3
| ClinicalTrial ID | NCT03235349 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 1, 2017 | Last Verified | March 13, 2019 |
| Sponsor | AbbVie | ||
Trial Record 4
| ClinicalTrial ID | NCT02738138 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | April 14, 2016 | Last Verified | May 9, 2018 |
| Sponsor | AbbVie | ||
Trial Record 5
| ClinicalTrial ID | NCT02642432 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | December 30, 2015 | Last Verified | October 26, 2017 |
| Sponsor | AbbVie | ||
Trial Record 6
| ClinicalTrial ID | NCT03219216 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Active, not recruiting |
| First Received | July 17, 2017 | Last Verified | November 1, 2018 |
| Sponsor | AbbVie | ||
| PubChem: | 66828839 |
| ChEMBL: | CHEMBL3545363 |